CD274 and non-small cell lung carcinoma: As of today, pembrolizumab alone is the standard first-line therapy for patients with PD-L1 expression >50% (FDA approval in October 2016), whereas pembrolizumab plus platinum-base chemotherapy is the treatment of choice for patients with PDL-L1 < 50% (FDA approval for non-squamous NSCLC in May 2017 and for squamous in October 2018).